Neurotoxicity and rare adverse events in BCMA-directed CAR T cell therapy: A comprehensive analysis of real-world FAERS data

Researchers sought to identify safety signals for ciltacabtagene autoleucel (cilta-cel) and idecabtagene vicleucel (ide-cel) by performing a cross-sectional analysis of adverse events reports reported with both therapies. For cilta-cel, they found significant safety signals for cerebrovascular accidents, intracranial hemorrhage, Haemophilus infections, and cytomegalovirus infections. For ide-cel, they found significant safety signals for parkinsonism, sarcoidosis, ventricular arrhythmias, and cardiac arrest.